These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15795183)

  • 1. Effect of PUVA therapy on electrodermal activity parameters in vitiligo patients.
    Dolu N; Ferahbaş A; Ozesmi C; Peker D; Açik C
    Auton Neurosci; 2005 Mar; 118(1-2):102-7. PubMed ID: 15795183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study.
    Bhatnagar A; Kanwar AJ; Parsad D; De D
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1381-5. PubMed ID: 17958845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An objective assessment of melanin in vitiligo skin treated with Balneo PUVA therapy.
    Hegyi V; Petrovajová M; Novotný M
    Skin Res Technol; 2014 Feb; 20(1):108-15. PubMed ID: 23800185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy.
    Yones SS; Palmer RA; Garibaldinos TM; Hawk JL
    Arch Dermatol; 2007 May; 143(5):578-84. PubMed ID: 17519217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: histopathological, immuno-histochemical and ultrastructural study.
    Anbar TS; El-Sawy AE; Attia SK; Barakat MT; Moftah NH; El-Ammawy TS; Abdel-Rahman AT; El-Tonsy MH
    Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):17-25. PubMed ID: 22211999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study.
    Sapam R; Agrawal S; Dhali TK
    Int J Dermatol; 2012 Sep; 51(9):1107-15. PubMed ID: 22909369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and side-effect profile of oral PUVA vs. oral PUVA sol in the treatment of vitiligo: a 36-week prospective study.
    Singh S; Khandpur S; Sharma VK; Ramam M
    J Eur Acad Dermatol Venereol; 2013 Nov; 27(11):1344-51. PubMed ID: 23066663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A.
    Westerhof W; Nieuweboer-Krobotova L
    Arch Dermatol; 1997 Dec; 133(12):1525-8. PubMed ID: 9420536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study.
    Bhatnagar A; Kanwar AJ; Parsad D; De D
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):638-42. PubMed ID: 17447977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term effects of PUVA therapy on Israeli patients with vitiligo].
    Vussuki E; Ziv M; Rosenman D; David M
    Harefuah; 2006 Jul; 145(7):483-5, 552, 551. PubMed ID: 16900734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo.
    Buckley DA; Rogers S
    Clin Exp Dermatol; 1996 Jan; 21(1):43-5. PubMed ID: 8689768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does autonomic dysfunction play a role in atopic dermatitis?
    Cicek D; Kandi B; Berilgen MS; Bulut S; Tekatas A; Dertlioglu SB; Ozel S; Saral Y
    Br J Dermatol; 2008 Sep; 159(4):834-8. PubMed ID: 18652587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study.
    Yalçin B; Sahin S; Bükülmez G; Karaduman A; Atakan N; Akan T; Kölemen F
    J Am Acad Dermatol; 2001 Apr; 44(4):634-7. PubMed ID: 11260538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo.
    Parsad D; Kanwar AJ; Kumar B
    J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):175-7. PubMed ID: 16441626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral psoralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation.
    Abdel-Naser MB; Hann SK; Bystryn JC
    Arch Dermatol; 1997 Dec; 133(12):1530-3. PubMed ID: 9420537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose prednisolone and psoralen ultraviolet A combination therapy in 36 patients with vitiligo.
    Lee Y; Seo YJ; Lee JH; Park JK
    Clin Exp Dermatol; 2007 Sep; 32(5):499-501. PubMed ID: 17608760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hyperglycemia on electrodermal activity in diabetic rats.
    Dolu N; Ozesmi C; Comu N; Süer C; Gölgeli A
    Int J Neurosci; 2006 Jun; 116(6):715-29. PubMed ID: 16753897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of vitiligo to PUVA therapy in Saudi patients.
    Tallab T; Joharji H; Bahamdan K; Karkashan E; Mourad M; Ibrahim K
    Int J Dermatol; 2005 Jul; 44(7):556-8. PubMed ID: 15985023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo.
    Wu CS; Lan CC; Wang LF; Chen GS; Wu CS; Yu HS
    Br J Dermatol; 2007 Jan; 156(1):122-9. PubMed ID: 17199578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA.
    Akyol M; Celik VK; Ozcelik S; Polat M; Marufihah M; Atalay A
    Eur J Dermatol; 2002; 12(1):24-6. PubMed ID: 11809591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.